UnitedHealthcare
Retevmo (selpercatinib)
Drugs for Cancer : Drugs for Cancer
  • Prior Authorization: RET-Fusion Non-Small Cell Lung Cancer:
    Documented Diagnosis: Yes
    Duration: 12 Month(s)
    Reauthorization Required: Yes

    RET-Fusion Thyroid Cancer, RET-Mutant MTC:
    Documented Diagnosis: Yes
    Medical Test Required: Yes
    Duration: 12 Month(s)
    Reauthorization Required: Yes

  • RET-Fusion Non-Small Cell Lung Cancer:
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: Yes
    Duration of Reauthorization: = 12 month(s)

    RET-Fusion Thyroid Cancer, RET-Mutant MTC:
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: Yes
    Reauthorization Required: Yes
    Duration of Reauthorization: = 12 month(s)

  • Quantity Limit: Maximum quantity of 124 per 31 Day(s). Maximum quantity 4 capsules per day.
  • Orally administered anticancer medication.